These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 3027338)

  • 1. Inhibitors of cyclic AMP phosphodiesterase. 1. Analogues of cilostamide and anagrelide.
    Jones GH; Venuti MC; Alvarez R; Bruno JJ; Berks AH; Prince A
    J Med Chem; 1987 Feb; 30(2):295-303. PubMed ID: 3027338
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibitors of cyclic AMP phosphodiesterase. 2. Structural variations of N-cyclohexyl-N-methyl-4-[(1,2,3,5-tetrahydro- 2-oxoimidazo[2,1-b]quinazolin-7-yl)-oxy]butyramide (RS-82856).
    Venuti MC; Jones GH; Alvarez R; Bruno JJ
    J Med Chem; 1987 Feb; 30(2):303-18. PubMed ID: 3027339
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A potent and selective inhibitor of cyclic AMP phosphodiesterase with potential cardiotonic and antithrombotic properties.
    Alvarez R; Banerjee GL; Bruno JJ; Jones GL; Littschwager K; Strosberg AM; Venuti MC
    Mol Pharmacol; 1986 Jun; 29(6):554-60. PubMed ID: 3012320
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibitors of cyclic AMP phosphodiesterase. 3. Synthesis and biological evaluation of pyrido and imidazolyl analogues of 1,2,3,5-tetrahydro-2-oxoimidazo[2,1-b]quinazoline.
    Venuti MC; Stephenson RA; Alvarez R; Bruno JJ; Strosberg AM
    J Med Chem; 1988 Nov; 31(11):2136-45. PubMed ID: 2846839
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anagrelide: a potent and selective inhibitor of platelet cyclic AMP phosphodiesterase enzyme activity.
    Gillespie E
    Biochem Pharmacol; 1988 Jul; 37(14):2866-8. PubMed ID: 2456068
    [No Abstract]   [Full Text] [Related]  

  • 6. Purification of cyclic adenosine monophosphate phosphodiesterase from human platelets using new-inhibitor Sepharose chromatography.
    Umekawa H; Tanaka T; Kimura Y; Hidaka H
    Biochem Pharmacol; 1984 Nov; 33(21):3339-44. PubMed ID: 6093810
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Selective inhibitor of platelet cyclic adenosine monophosphate phosphodiesterase, cilostamide, inhibits platelet aggregation.
    Hidaka H; Hayashi H; Kohri H; Kimura Y; Hosokawa T; Igawa T; Saitoh Y
    J Pharmacol Exp Ther; 1979 Oct; 211(1):26-30. PubMed ID: 226672
    [No Abstract]   [Full Text] [Related]  

  • 8. Inhibitors of blood platelet cAMP phosphodiesterase. 2. Structure-activity relationships associated with 1,3-dihydro-2H-imidazo[4,5-b]quinolin-2-ones substituted with functionalized side chains.
    Meanwell NA; Pearce BC; Roth HR; Smith EC; Wedding DL; Wright JJ; Buchanan JO; Baryla UM; Gamberdella M; Gillespie E
    J Med Chem; 1992 Jul; 35(14):2672-87. PubMed ID: 1321910
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of cyclic AMP phosphodiesterase activity and myocardial contractility: effects of cilostamide, a novel PDE inhibitor, and methylsiobutylxanthine on rabbit and canine ventricular muscle.
    Endoh M; Satoh K; Yamashita S
    Eur J Pharmacol; 1980 Aug; 66(1):43-52. PubMed ID: 6157546
    [No Abstract]   [Full Text] [Related]  

  • 10. Potent effects of novel anti-platelet aggregatory cilostamide analogues on recombinant cyclic nucleotide phosphodiesterase isozyme activity.
    Sudo T; Tachibana K; Toga K; Tochizawa S; Inoue Y; Kimura Y; Hidaka H
    Biochem Pharmacol; 2000 Feb; 59(4):347-56. PubMed ID: 10644042
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tissue and substrate specificity of inhibition by alkoxy-aryl-lactams of platelet and arterial smooth muscle cyclic nucleotide phosphodiesterases relationship to pharmacological activity.
    Lugnier C; Stierlé A; Beretz A; Schoeffter P; Lebec A; Wermuth CG; Cazenave JP; Stoclet JC
    Biochem Biophys Res Commun; 1983 Jun; 113(3):954-9. PubMed ID: 6307307
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Imidazoquinoline derivatives: potent inhibitors of platelet cAMP phosphodiesterase which elevate cAMP levels and activate protein kinase in platelets.
    Seiler S; Gillespie E; Arnold AJ; Brassard CL; Meanwell NA; Fleming JS
    Thromb Res; 1991 Apr; 62(1-2):31-42. PubMed ID: 1649498
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Demonstration of functional compartments of cyclic AMP in rat platelets by the use of phosphodiesterase inhibitors.
    Ashida S; Sakuma K
    Adv Second Messenger Phosphoprotein Res; 1992; 25():229-39. PubMed ID: 1313259
    [No Abstract]   [Full Text] [Related]  

  • 14. Electrochemical evaluation of the interaction between ascorbic acid and the cardiotonic drug RS-82856.
    Visor GC; Lin LH; Kenley RA; Venuti MC; Alvarez R
    Drug Des Deliv; 1987 Dec; 2(2):121-8. PubMed ID: 2855568
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibitors of blood platelet cAMP phosphodiesterase. 4. Structural variation of the side-chain terminus of water-soluble 1,3-dihydro-2H-imidazo[4,5-b]quinolin-2-one derivatives.
    Meanwell NA; Hewawasam P; Thomas JA; Wright JJ; Russell JW; Gamberdella M; Goldenberg HJ; Seiler SM; Zavoico GB
    J Med Chem; 1993 Oct; 36(22):3251-64. PubMed ID: 8230115
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 7-Bromo-1,5-dihydro-3,6-dimethylimidazo[2,1-b]quinazolin-2(3H)- one (Ro 15-2041), a potent antithrombotic agent that selectively inhibits platelet cyclic AMP-phosphodiesterase.
    Muggli R; Tschopp TB; Mittelholzer E; Baumgartner HR
    J Pharmacol Exp Ther; 1985 Oct; 235(1):212-9. PubMed ID: 2995647
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibitors of blood platelet cAMP phosphodiesterase. 3. 1,3-Dihydro-2H-imidazo[4,5-b]quinolin-2-one derivatives with enhanced aqueous solubility.
    Meanwell NA; Dennis RD; Roth HR; Rosenfeld MJ; Smith EC; Wright JJ; Buchanan JO; Brassard CL; Gamberdella M; Gillespie E
    J Med Chem; 1992 Jul; 35(14):2688-96. PubMed ID: 1321911
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 8-Methoxyquinolines as PDE4 inhibitors.
    Billah M; Buckley GM; Cooper N; Dyke HJ; Egan R; Ganguly A; Gowers L; Haughan AF; Kendall HJ; Lowe C; Minnicozzi M; Montana JG; Oxford J; Peake JC; Picken CL; Piwinski JJ; Naylor R; Sabin V; Shih NY; Warneck JB
    Bioorg Med Chem Lett; 2002 Jun; 12(12):1617-9. PubMed ID: 12039575
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A novel class of cardiotonic agents: synthesis and biological evaluation of pyridazino[4,5-b]indoles with cyclic AMP phosphodiesterases inhibiting properties.
    Monge A; Aldana I; Losa MJ; Font M; Castiella E; Frechilla D; Cenarruzabeitia E; Martinez de Irujo JJ; Lopez-Unzu J; Alberdi E
    J Pharm Sci; 1993 May; 82(5):526-30. PubMed ID: 8395600
    [TBL] [Abstract][Full Text] [Related]  

  • 20. QSAR study of phosphodiesterase inhibitory activity of imidazo[2,1-b]-quinazolines: active site analysis.
    Prabhakar YS
    Drug Des Deliv; 1989 Dec; 5(2):81-91. PubMed ID: 2577989
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.